tebentafusp: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
tebentafusp: clinical details
Prescribing considerations
- Confirm HLA-A*02:01 status using a validated genotyping assay before treatment.
- Administration requires clinicians experienced with anticancer immunotherapy and immediate access to supportive medicines and resuscitation equipment.
- Assess cardiovascular history, renal and hepatic function, pregnancy potential and concomitant narrow-therapeutic-index CYP450 substrates.
- Record the product name and batch number to maintain biological-medicine traceability.
Contraindications and cautions
- Hypersensitivity to tebentafusp or any formulation excipient.
- Use caution in severe renal impairment, moderate or severe baseline hepatic impairment, significant cardiac disease or QT prolongation because clinical experience is limited.
Monitoring
- Observe closely for cytokine release syndrome, hypotension, hypoxia and acute skin reactions, particularly during initial administrations.
- Monitor vital signs and hydration status around administration.
- Check liver enzymes, bilirubin, blood count, electrolytes and other clinically indicated biochemistry.
- Perform ECG monitoring during early treatment and subsequently when clinically indicated; investigate QT prolongation and correct contributory electrolyte abnormalities.
Clinical pharmacology
Tebentafusp is a recombinant bispecific fusion protein comprising a high-affinity T-cell receptor directed at the gp100 peptide–HLA-A*02:01 complex and an anti-CD3 effector domain. It redirects polyclonal T cells independently of their native specificity, causing cytokine release and targeted tumour-cell lysis. As a protein therapeutic, it is expected to undergo catabolic degradation to peptides and amino acids.
Formulation and product differences
- The selected UK product is a clear, colourless to slightly yellow concentrate in a single-use vial.
- It requires aseptic dilution in sodium chloride solution containing human albumin before intravenous administration.
- The vial must not be shaken, and closed-system transfer devices must not be used during preparation.
tebentafusp preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 200 micrograms/mL
tebentafusp interactions
Formal interaction studies have not been performed. Temporary cytokine release after starting tebentafusp may reduce CYP450 enzyme activity and alter exposure to some medicines.
Narrow-therapeutic-index CYP450 substrates, including warfarin or ciclosporin
Toxicity or medicine concentrations may increase temporarily, so additional clinical, blood-test or concentration monitoring may be needed.
Replacement corticosteroids for adrenal insufficiency
The prescriber may need to review corticosteroid requirements while tebentafusp is being given.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.